Kanabo Announces Partnership With Medocann Group to Exclusively Develop and Distribute Unique Cannabis Strains & Products for UK and German Markets

CANNANNEW REPORT

● Cannabis flowers and extracts to be developed for specific medical conditions ● Kanabo to exclusively distribute the co-developed sought after product in UK and Germany ● Partnership estimated to generate €9 million in sales over the first three years LONDON–(BUSINESS WIRE)–Kanabo, one of Europe’s fastest-growing medical cannabis R&D companies that focuses on the distribution of cannabis-derived products for medical patients, and non-THC products for CBD consumers, has signed a partnership agreement with the Medocann Pharma Ltd. to develop new products that will target specific medical conditions. The deal gives Kanabo exclusive distribution rights to the co-developed products into the growing German and UK cannabis markets. Medocann is an established medical-grade cannabis producer with an indoor, hydroponic facility located in central Israel and has a library of proprietary cannabis genetics. Medocan’s medical cannabis is grown in a fully controlled environment, without the use of pesticides or insecticides. Medocann has GACP & IMC GAP certification for commercial propagation and cultivation and is currently selling its ultra-premium products in Israel. The partnership agreement between Kanabo and Medocann will focus on the co-development of new and novel products as well as on the co-development of new and unique cannabis strains. These new strains and products will be targeted at specific medical indications through the combination of Kanabo’s preclinical data on the effect of cannabis on different illnesses and Medocann’s genetics bank, strain development expertise and innovative cultivation capabilities. 1,000kg of Medocann’s precisely grown cannabis flowers and extracts will be integrated into co-branded products that will be available for sale within the first three years of the agreement, which the board estimates will generate sales of up to €9m in aggregate. The agreement includes the exclusive rights to distribute the co-developed products into both the UK and German cannabis markets. The deal will take…

Excerpt only …
READ MORE BELOW
Source : Kanabo Announces Partnership With Medocann Group to Exclusively Develop and Distribute Unique Cannabis Strains & Products for UK and German Markets

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.